Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 9, 2024
Emerging Company Profile

Karuna team, backers reunite for neuropsychiatry play Seaport’s launch

PureTech’s Zohar, Karuna’s Paul among team advancing prodrug candidates for anxiety and depression that avoid hepatic absorption
BioCentury | Mar 21, 2023
Product Development

March 20 Quick Takes: Latest data add to Karuna’s case in schizophrenia

Plus: two Sangamo partnerships end, Gilead adds Nurix’s degrader
BioCentury | Nov 10, 2021
Deals

Zai breaks into neuroscience with Karuna deal, adds cancer asset from Blueprint

Cross-border company lays out $60M in pair of deals
BioCentury | Mar 18, 2019
Financial News

Karuna looks past schizophrenia with $68M series B

BioCentury | Aug 3, 2018
Finance

Karuna’s CNS double play

How Karuna plans to deploy $42M A round to revive xanomeline’s development
BioCentury | Aug 3, 2018
Financial News

Karuna raises $42M series A

BioCentury | Aug 2, 2018
Financial News

Karuna raises $42M series A

BioCentury | Apr 6, 2018
Company News

Dermavant acquires compound from TheraVida

Items per page:
1 - 10 of 17
Username